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GremlinBone morphogenetic proteins (BMPs) are increasingly being used clinically to enhance fracture repair and
healing of non-unions. However, the potential efﬁcacy of supraphysiological dosing for clinical results warrants
further clariﬁcation of the BMP signaling pathway in human fracture healing. As BMP signaling can beﬁne-tuned
at numerous levels, the role of BMP-inhibitors has become a major focus. The aim of the present study was to
document co-expression of BMPs, pSmad 1/5/8, and BMP-inhibitors in human fracture callus and human non-
unions. Using human tissue of fracture callus (n=14) and non-unions (n=4) we documented expression of
BMPs (BMP2, BMP3 and BMP7), pSmad 1/5/8 and the BMP-inhibitors noggin, gremlin, chordin, Smad-6,
Smad-7 and BAMBI. Co-expression of pSmad 1/5/8, BMPs and BMP-inhibitors was noted in the osteoblasts of
fracture callus as well as of non-unions. Expression of BMP-inhibitors was generally stronger in non-unions
than in fracture callus. The most pertinent differences were noted in the cartilaginous tissue components.
Expression of BMP2 in chondrocytes was markedly decreased in non-unions compared to fracture callus and
that of BMP7 was almost completely absent. Expression of BMP-inhibitors was almost the same in osteoblasts,
chondrocytes and ﬁbroblasts of fracture callus and well as in non-unions. Interestingly, although BMP ligands
were present in the chondrocytes and ﬁbroblasts of non-unions, they did not co-express pSmad 1/5/8 suggesting
that BMP signaling may have been inhibited at some point before Smad 1/5/8 phosphorylation.
These results suggest co-expression of BMP, pSmad 1/5/8 and BMP-inhibitors occurs in human fracture callus as
well as non-unions but the relative expression of BMPs vs. BMP-inhibitors was different between these two tis-
sue types. In contrast to our expectations, the expression of BMP inhibitors was comparable between fracture
callus and non-unions, whereas the expression of BMPs was notably lower in the cartilaginous component of
the non-unions in comparison to fracture callus. Based on these results, we believe that aberrations in the
BMP-signaling pathway in the cartilaginous component of fracture healing could inﬂuence clinical fracture heal-
ing. An imbalance between the local presence of BMP and BMP-inhibitors may switch the direction towards
healing or non-healing of a fracture.
© 2012 Elsevier Inc. Open access under CC BY-NC-ND license.Introduction
Bone healing is a complex regenerative process initiated in response
to a fracture; with the ﬁnal aim of restoring skeletal function. Over the
last 2 decades, this well orchestrated cascade of events has become
increasingly understood [1]. Interestingly, bone healing seems to reca-
pitulate many events seen in bone development and embryogenesis
[1–3]. The key drivers of this process are cytokines, platelets and growth
factors, of which bone morphogenetic proteins (BMPs) have emerged
as critical players.
BMPs are members of the pleiotropic Transforming Growth Factor-
Beta (TGF-β) family [4]. More than 20 BMPs are currently known, and
their characteristic feature is the capacity to induce endochondral
bone formation [4–12]. Starting after birth, BMPs play a critical role inminique.lauzier@hotmail.com
-NC-ND license.maintenance of bone mass through inducing commitment of mesen-
chymal cells towards cells of the osteoblastic lineage, and they
also enhance the differentiated function of the osteoblast. Analysis of
genetically modiﬁed mouse models with various null mutations,
dominant-negative or conditional knockouts of BMP ligands, BMP
receptors (BMPRs) or Smad proteins, has clearly shown the functional
relevance of the BMP signaling cascade in skeletal formation and repair
[13]. In addition, naturally occurring mutations of BMPs and BMPR in
humans are associated with skeletal abnormalities [14].
The BMP signals are mediated by type I and type II serine/threonine
kinase transmembrane receptors (BMPRIA, BMPRIB and BMPRII) [4,11].
These receptors are expressed at different levels in different tissues.
BMP binding to BMPRs activates Smad signaling that is translocated
to the nucleus. The Smads are intracellular proteins than can be broadly
divided in three classes: 1) receptor regulated Smads (R-Smads) such as
Smad 1/5/8; 2) co-Smads, such as Smad-4; 3) inhibitory Smads (Smad-
6 and Smad-7). It has also been shown that the actions of BMPs are
tempered by inhibitors or antagonists, indicating the existence of local
Table 1
Summary of patient data.
Specimen Age/sex Location Time since fracture (weeks)
Fracture callus 21 M Acetabulum 2
15 M Acetabulum 5
34 M Distal radius 4
39 M Proximal femur 8
43 F Distal femur 6
44 M Humerus shaft 10
28 M Distal humerus 3
35 M Femur shaft 3
10 F Foot 2
43 M Pelvis 3
33 M Distal ﬁbula 5
70 M Humerus shaft 6
Non-union 69 M Tibia shaft 56
38 M Ulna shaft 24
37 M Tibia shaft 24
51 F Femur shaft 272
60 P. Kloen et al. / Bone 51 (2012) 59–68feedback mechanisms to modulate BMP cellular activities [14–16].
The antagonists function at different levels of the BMP-signaling cas-
cade: extracellular at the BMP-BMPR interaction (e.g. prevention of
BMP binding to its receptors by noggin, chordin, and gremlin), by
expression of membrane pseudo-receptors (e.g. BAMBI), and at the
intracellular level (Smad-6 and Smad-7). Others have also been de-
scribed (e.g. Ski).
After numerous animal studies showed the presence of BMPs,
BMPRs and some of their antagonists [6,17–19] in fracture healing and
distraction osteogenesis [20–26], we were the ﬁrst to show expression
of BMPs, BMPRs and intracellular signaling proteins (Smads) in
human fracture and non-union tissue [7,8]. Surprisingly, our work
showed that expression patterns did not differ between healing and
non-healing fractures, suggesting that differences in healing capacity
are not directly due to level of expression of BMPs, their receptors,
and/or intracellular Smads. The ﬁrst description of BMP-inhibitors in
human fracture tissue was done by Kwong et al. in 2009 [27].
Although many questions remain for a complete understanding,
scientists and clinicians are keen to leverage what is already known
for clinical application. Preclinical studies have led to the clinical use
of BMP2 and BMP7 [11,28,29]. So far, however, efﬁcacy seems to be
no better than autologous bone graft, with a key disadvantage being
exogenous application is more costly [30]. Also, the clinical dosage
needed is 100–1000 times higher than endogenous BMPs [28], and
complications mostly related to the off-label use of BMPs have been
reported [11,29].
To improve the effectiveness of BMPs as treatment, there are many
aspects that still need clariﬁcation.What is well known is that BMP sig-
naling can beﬁne-tuned at numerous levels at almost any step along the
pathway [13–16,31]. Recently, the role of BMP-inhibitors (e.g. noggin,
gremlin, chordin) and the extent to which they can be used as a control
mechanism have received much attention [13–16,31]. Therefore, it
seems possible that abnormal BMP signaling caused by increased ex-
pression of BMP-inhibitors could be related to unsuccessful bone heal-
ing. We and others have speculated on focusing on the BMP-inhibitors
in bone healing, which is now emerging as a therapeutic target [32].
The objective of the current study was to document naturally oc-
curring levels of BMPs and their inhibitors in human fractures and
non-unions. Our hypothesis was that the balance between BMP and
BMP-inhibitors differs between healing and non-healing human frac-
tures, which would imply an interventional opportunity. In addition,
we also set out to study their co-expression using double and triple
immunohistochemistry staining. Fundamental to our hypothesis is a
better understanding at the molecular level of why certain fractures
heal and others do not.
Materials and methods
Specimens
Fracture callus and non-union tissue was obtained during surgery
of 16 different patients at the time of operative repair or revision sur-
gery of the fracture (n=12) or hypertrophic non-union (n=4).
Three fractures involved the acetabulum (n=2) or pelvis (n=1).
All other fractures and non-unions pertained to the appendicular
skeleton. Although more patients were treated during this period,
representative tissue availability was limited. The deﬁnition of a
non-union was a fracture that had not healed within 6 months. All
patients were treated by the senior author (PK) between 2001 and
2010. Patient characteristics are listed in Table 1.
Fracture patients were between 10 and 70 years of age and other-
wise in good health. There were 10 males and 2 females. Time to callus
harvest ranged from 2 to 10 weeks. Non-union patients were between
37 and 69 years of age and otherwise in good health. There were 3
males and 1 female. Approval of the Institutional Review Board (IRB)
was obtained where appropriate. Oral consent for removal of the tissueand its storage in the tissue bank for research purposes was obtained
from each patient. Individual consent for this speciﬁc project was
waivered by the ethics committee of the remaining two hospitals since
the research was performed on “waste” material, stored in a coded
fashion. Indications for surgery were nascent (impending) malunion,
non-union, and failure of ﬁxation or fractures that were operated on in
a delayed fashion. All fractures and non-unions have subsequently
successfully healed.
After removal from patients, specimens were placed in 10% neutral
buffered formalin for 24 h and subsequently decalciﬁed – if needed –
in 10% ethylenediamine tetra acetic acid (EDTA), pH 7.2. The tissue
was then routinely processed and embedded in parafﬁn wax. Sequen-
tial sections of 5–7 μm thick were prepared for haematoxylin and
eosin (H&E) staining and immunohistochemistry (IHC).Immunohistochemistry
For immunohistochemistry, sampleswere ﬁxed in 4% paraformalde-
hyde overnight, decalciﬁed in 20% ethylene diamine tetra-acetic acid for
3 weeks, embedded in MMA (methylmethacrylate), and sectioned
using a Leica RM 2255 microtome (Leica Microsystems, Richmond
Hill, ON, Canada). Following deparafﬁnization and hydration, endoge-
nous peroxidase activity was blocked using 10% hydrogen peroxide
for 10 min. Nonspeciﬁc binding was blocked by incubating samples in
phosphate-buffered saline containing 10% normal horse serum for
20 min. Commercially available polyclonal goat antibodies were used
for the detection of the following proteins: BMP2, BMP3, BMP7, noggin,
gremlin, chordin, pSmad 1/5/8, Smad-6, Smad-7, and BAMBI (all from
Santa Cruz Biotechnologies, Santa Cruz, CA, USA, 1:100 dilution in 1%
goat serum).
Tissue sectionswere probedwith the polyclonal goat antibody over-
night at 4 °C in a humidiﬁed chamber. For negative controls, we omitted
the primary antibody. We then incubated the sections with a biotiny-
lated mouse anti-goat secondary antibody (Santa Cruz Biotechnologies,
Santa Cruz, CA, USA, 1:400 dilutions in 1% normal goat serum) for
30 min at room temperature in a humidiﬁed chamber. Sections were
stained using the avidin–biotin complex method for 30 min, followed
by DAB-peroxidase staining. Finally, we counterstained sections with
hematoxylin and mounted with Permount (Fisher Scientiﬁc, Montreal,
Canada). Photomicrographs of the tissues were taken under 10× and
40× magniﬁcations using a Leica microscope (Leica Microsystems,
Richmond Hill, ON, Canada) attached to a Q-Imaging camera (Olympus
DP70, Japan). For each frame tested, we also performed a negative
control where the same procedure was performed but omitting the
primary antibodies.
Table 2
Immunohistochemistry results of BMP2, BMP3, BMP7, BMP-antagonists and pSmad 1/5/8.
Protein Tissue OB OC Non-HC C FB
BMP2 Fracture callus + − ++ ++ +
Nonunion ++ + + + +
BMP3 Fracture callus + + + ++ +
Nonunion + + − − −
BMP7 Fracture callus + + + ++ +
Nonunion + + − − −
Noggin Fracture callus + + + ++ +
Nonunion + + + +++ +
Chordin Fracture callus ++ ++ ++ +++ ++
Nonunion ++ ++ − − −
Gremlin Fracture callus ++ ++ +++ ++ ++
Nonunion ++ ++ ++ +++ +++
BAMBI Fracture callus +++ − − − −
Nonunion ++ − − − −
Smad-6 Fracture callus + + + − +
Nonunion ++ + ++ + −
Smad-7 Fracture callus +++ + +++ ++ ++
Nonunion +++ ++ ++ + +
pSmad 1/5/8 Fracture callus + + − ++ ++
Nonunion ++ + − − −
−, No positive staining; +, less than 25% of cells stained positive, ++, 25 to 50% cells
stained positive, +++, 50 to 75% cells stained positive, ++++, over 75% cells stained
positive. OB: Osteoblasts; OC: Osteoclasts; Non-HC: Non-hypertrophic chondrocytes;
C: Chondrocytes; FB: Fibroblasts.
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Although immunohistochemistry is known as a qualitative tech-
nique used for description of cellular and extracellular components
that stain positively, our laboratory has successfully developed a
technique to semi-quantitatively evaluate our results, based on the
percentage of positively staining cells. This technique has been previ-
ously reported for mandibular [21] and long bone distraction osteo-
genesis [20,22–24]. We have utilized the same technique in the
current study. The grading scheme included: + represents b25% of
the cells stained positively for the protein of interest, ++ represents
25% to 50% of cells stained positive, +++ represents 25% to 75% of
cells stained positive, ++++ represented more than 75% of cells
stained positive, and lastly − denoted no cells stained positively.Fig. 1. Histological section (Goldner's trichrome) of fracture callus (upper row) and non-unio
hypertrophic chondrocytes (C) of a non-union. Also shown, positive staining of BMP2 and B
callus and of BMP7 in osteoclasts (OC) of a non-union (magniﬁcation 400×).The number of cells expressing the various proteins is assessed by
cell counting in a superimposed grid. Sections were analyzed blindly
in triplicates by an immunohistochemistry specialist (DL). The aver-
ages of all results were recorded (Table 2). Chondrocytes (hypertro-
phic and non-hypertrophic), osteoblastic, and ﬁbroblastic cells were
identiﬁed morphologically and scored independently. There were 16
samples: twelve fracture callus and four non-unions and there were
10 sections from each sample for a total of 160 sections that were an-
alyzed for cell count.
Immunoﬂuorescence
The ﬁxed tissues were embedded in parafﬁn. Sections of 6 μm
were deparafﬁnized and hydrated. Nonspeciﬁc binding was blocked
by incubation in phosphate-buffered saline containing 2% normal
donkey serum for 30 min. For immunoﬂuorescence staining, sections
were incubated with both polyclonal primary goat and rabbit (or goat
and monoclonal mouse) antibodies (Santa Cruz Biotechnologies,
Santa Cruz, CA, USA) in a humidiﬁed chamber at 4 °C overnight
(1:100 dilution in phosphate-buffered saline with 1% normal donkey
serum). For the second antibody, combination of Alexa Fluor donkey
anti-goat 488 and donkey anti-rabbit 555 (Invitrogen, Grand Island,
NY, USA) were incubated for 60 min at room temperature at a dilu-
tion of 1:600 for the anti goat and 1:800 for the anti-rabbit.
For the combination of polyclonal goat andmonoclonalmouse, both
Alexa Fluor donkey anti-goat 488 and donkey anti-mouse 555 were in-
cubated for 60 min at room temperature at a dilution of 1:600. Finally
for nuclear staining, sections were incubated 30 min with DAPI
(Sigma-Aldrich, Oakville, Ontario, Canada) then mounted with perma-
nent aqueous mounting media. Before taking the pictures for immuno-
ﬂuorescence, the tissues were ﬁrst examined under “phase contrast” in
order to visualize the various types of cells, then the pictures were
acquired with different ﬂuorochromes; DAPI (UV), Alexa Fluor 488
(green) and the Alexa Fluor 555 (red).
Images were captured with a ﬂuorescent microscope (Leica model
with software ACDSee, magniﬁcation 630×). Superposition of images
was performed with Adobe Photoshop software. The following were
analyzed BMP2, BMP7, BMP3, BAMBI, noggin, gremlin, pSmad 1/5/8,
chordin, Smad-6 and Smad-7.n (lower row). The most signiﬁcant ﬁnding is decreased staining of BMP2 and BMP7 in
MP7 in osteoblasts (OB) of non-unions, BMP2 in osteoblasts and ﬁbroblasts of fracture
Fig. 2. Histological section showing expression of BMP antagonists and pSmad 1/5/8 in a non-union (magniﬁcation 400×). No staining for chordin in hypertrophic and non-
hypertrophic chondrocytes (C) and positive staining for chordin in osteoblasts (OB) and osteoclasts (OC). Very strong staining of gremlin in cartilaginous cells (hypertrophic
and non-hypertrophic chondrocytes). Staining of noggin in cartilaginous cells (hypertrophic and non-hypertrophic chondrocytes) and osteoblasts. Minimal staining of pSmad
1/5/8 in hypertrophic chondrocytes. Smad-6 and Smad-7 showing positive and negative staining in hypertrophic and non-hypertrophic chondrocytes.
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Histology
Similar to our previous work, standard light microscopy of H&E-
stained histological sections revealed callus formation at variousFig. 3. Histological section showing expression of BMP antagonists and pSmad 1/5/8 in fract
in cartilaginous cells (C). Gremlin showing intense staining in hypertrophic chondrocytes. N
5/8 showing mixed negative and positive staining in hypertrophic chondrocytes. Smad-6 sh
staining in hypertrophic chondrocytes.stages of development in all fracture cases [7]. Most specimens con-
tained a mixture of endochondral and intramembranous ossiﬁcation.
There were also interspersed areas of stroma formed by ﬁbroblast-
like cells and areas of new blood vessel formation. We did not attempt
to correlate the maturity of the callus with the time since fracture.
For ethical reasons we could only remove callus tissue that wasure callus (magniﬁcation 400×). Chordin showing mixed positive and negative staining
oggin showing staining in hypertrophic and non-hypertrophic chondrocytes. pSmad 1/
owing almost no staining in hypertrophic chondrocytes while Smad-7 showing intense
Fig. 4. Immunoﬂuorescent triple staining showing co-localization of BMP2, pSmad 1/5/8 and DAPI in fracture callus in hypertrophic chondrocytes (C) and ﬁbroblasts (FB)
(magniﬁcation 630×).
Fig. 5. Immunoﬂuorescent triple staining showing co-localization of BMP2, noggin and DAPI in hypertrophic chondrocytes of fracture callus (magniﬁcation 630×).
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Fig. 6. Immunoﬂuorescent triple staining showing co-localization of BMP7, noggin and DAPI in hypertrophic chondrocytes of fracture callus (magniﬁcation 630×).
Fig. 7. Immunoﬂuorescent triple staining showing co-localization of BMP2, pSmad 1/5/8 and DAPI in hypertrophic chondrocytes (HC) of a non-union (magniﬁcation 630×,
FB: ﬁbroblast).
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65P. Kloen et al. / Bone 51 (2012) 59–68interfering with operative repair of the bone and we could not obtain
control tissue from the same patient. Non-unions revealed a mixture
of different tissue types. There were foci of woven bone interspersed
by areas of ﬁbrous tissue with presence of blood vessels.
Immunohistochemistry
In general, our results showed that expression of BMP-inhibitors
was stronger than BMP ligands. In addition, active BMP signaling as
exempliﬁed by presence of pSmad 1/5/8 was present in osteoblasts
of all specimens, fracture callus and non-union. The main differences
were found to be in the chondrocytes and ﬁbroblasts.
Expression of BMP2, BMP7 and pSmad 1/5/8
Overall, our results showed decreased or no expression of BMPs in
cartilaginous cells (hypertrophic and non-hypertrophic) of non-unions
compared to fracture callus. The expression of BMP2 was decreased in
cartilaginous cells (hypertrophic and non-hypertrophic chondrocytes)
of non-unions while it was increased in osteoblasts and osteoclasts of
non-unions. On the other hand, there was little expression of BMP7 in
hypertrophic and non-hypertrophic chondrocytes and ﬁbroblasts of
non-unions, but equal expression in osteoblasts and osteoclasts of
both groups (Table 2 and Fig. 1). Although the expression of pSmad
1/5/8was decreased in cases of non-unions compared to fracture callus,
it was still present in osteoblasts and hypertrophic chondrocytes of
non-unions (Table 2 and Figs. 1–3), conﬁrming our previous report
showing active BMP signaling in non-unions [8].
Expression of BMP-inhibitors
The expression of noggin and gremlin was present in all cell types
of all specimens. On the other hand, BMP3 (generally referred to as a
BMP-inhibitor) and chordin were not expressed in chondrocytes
(hypertrophic and non-hypertrophic) of non-unions. Results of the ex-
pression of Smad-6 and Smad-7 were mixed. Although both Smad-6
and Smad-7 are inhibitors, their expression did not follow the sameFig. 8. Immunoﬂuorescent triple staining showing co-localization of BMP2, noggin an
OB: osteoblast).pattern. When comparing sections of fracture callus with those of
non-unions, our results showed increased expression of Smad-6 in
osteoblasts, hypertrophic and non-hypertrophic chondrocytes of non-
unions, Smad-7 showed equal expression in osteoblasts of both fracture
callus and non-unions, while decreased expression in hypertrophic and
non-hypertrophic chondrocytes of non-unions. Representative staining
images are shown in Figs. 2 and 3.Co-staining and co-localization by double and triple immunoﬂuorescence
analysis
In general, results of double and triple immunoﬂuorescence staining
showed co-localization of BMP ligands with inhibitors, in all sections of
both fracture callus and non-unions. There was also decreased staining
of BMP2 in the non-unions (representative images are shown in
Figs. 4–8). A summary of the expression data is shown in Table 2.Discussion
The results of this study support our hypothesis that the balance
between expression of endogenous BMP ligands and BMP-inhibitors in
non-unions is different than in normal fracture healing. Speciﬁcally, our
results show that in chondrocytes, expression of BMP2 was markedly
decreased in non-unions and that of BMP7 was almost completely
absent. On theother hand, expressionof BMP-inhibitors (noggin, gremlin,
Smad-6 and Smad-7) was almost the same in osteoblasts, chondrocytes
and ﬁbroblasts of both fracture callus and non-unions. Although these
data are consistent with our hypothesis, we had expected that this
“imbalance” was due to an increased expression of BMP-inhibitors in
non-unions. The current data suggest, however, that it is due to decreased
expression of BMPs. In our previous study on delayed and non-
unions, we demonstrated that BMP2, BMP4 and BMP7, BMPRs and
pSmad 1/5/8 were present inmost non-unions in osteoblasts and ﬁbro-
blasts [8]. However, in that study, we did not speciﬁcally analyze the ex-
pression of these BMP-related proteins in cartilage cells and we did not
compare our ﬁndings with those of normal fracture healing.d DAPI in hypertrophic chondrocytes (HC) of a non-union (magniﬁcation 400×,
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nists, being a potential cause of the development of non-unions, was
ﬁrst suggested by Niikura et al. who compared global gene expression
for osteogenic BMPs and their inhibitors in a rat fracture and atrophic
non-union model [33]. They concluded that non-unions were not
accounted for by up-regulation of BMP-inhibitors. Others studies
have investigated the same question with various results [27,34–37]
(see Tables 3 and 4 for a summary of the current literature on the
balance between BMPs and BMP-inhibitors in human and animal
fractures and non-unions). Thus, although we and others agree on the
presence of a different balance between BMP and BMP-inhibitors in
fractures vs. non-unions, there is disagreement on the nature of this
“imbalance”. Namely, the question remains as to whether the discon-
nect is caused by a suboptimal expression of BMPs, or by increased pres-
ence of BMP-inhibitors, or possibly by both of these factors.
A potential explanation of these differences in expression of BMPs
and their inhibitors could be the difference in timing of the non-union
analysis, species, location of the non-union and type of non-union
(atrophic vs. hypertrophic) and, most importantly, by the complexity
and tight control of the BMP signaling pathway. Results of our immu-
noﬂuorescence studies emphasize the magnitude of this control,
where almost all staining for BMP2 and BMP7 was co-localized with
BMP-inhibitors, suggesting an intimate interaction between them.
There is enough evidence in the literature that BMP-inhibitors do
play a major role in bone healing and formation [38–42]. However, to
date, there are no studies evaluating the effects of inhibiting one or
more of these inhibitors on fracture healing in humans. We andTable 3
Summary of reports on BMP signaling components in human fracture healing and non-uni
Author–year Tissue analyzed BMPs analyzed
Kloen–2002 [8] Delayed union (n=4)
Non-union (n=17)
BMP2, BMP3, BMP4,
BMP7, BMPRIA, BMPRIB,
BMPRII, pSmad 1/5/8
Kloen–2003 [7] Fracture callus (n=5) BMP2, BMP3, BMP4,
BMP7, BMPRIA, BMPRIB,
BMPRII, pSmad 1/5/8
Kwong–2009 [27] Fracture callus (n=15) BMP2, BMP14, noggin,
chordin
Fajardo–2009 [35] Hypertrophic non-union
(n=15) extracting healing
tissue as well as non-union
tissue from the same
patient
BMP2, BMP4, BMP5,
BMP6, BMP7, BMP8,
BMPRIA, BMPRIB,
BMPRII, noggin, chordin,
drm, gremlin, follistatin
Kwong–2009 [34] Fracture callus (n=8)
Non-union (n=7)
BMP2, BMP14, noggin,
chordin
Present study–2012 Fracture callus (n=12)
Non-union (n=4)
BMP2, BMP3, BMP7,
pSmad 1/5/8, noggin,
chordin, gremlin, BAMBI,
Smad-6, Smad-7
BMPR: BMP receptor; IHC: immunohistochemistry; qPCR: quantitative PCR.others have hypothesized that local application of BMPs in humans
will lead to a dose-dependent increase in expression of antagonists,
limiting their functional therapeutic application [32]. Ideally, using
inhibition, we would be able to maximize BMP intrinsic activity and
eliminate the need for high – and expensive – exogenous BMP dosing.
Furthermore, another advantage of addressing the inhibitors rather
than the ligands is that noggin, gremlin and chordin bind to several
BMPs [43–45]. This has tremendous therapeutic potential, as pharma-
cological targeting of any of these inhibitors should up-regulate the
expression of not a single but several BMPs. Interestingly, recently
BMP variants have been engineered to overcome inhibition by nog-
gin. This has the additional potential to allow development of more
effective, second generation BMPs with more potent clinical applica-
bility [43,46].
Inherent weaknesses of the current study are the obvious hetero-
geneity of the patients, relatively small sample size, the different time
to sampling and the variety in location of the fractures and non-
unions. Although it is not possible to rule out intrinsic variability in
the current data, it is not feasible to obtain a large number of compa-
rable fracture and/or non-unions in similar bones and patients.
The current study, although limited in sample size, has several im-
portant and relevant strengths. For example, due to timing of most
fracture surgery, which is mostly done within 2–3 weeks after injury,
the availability of human fracture callus is notoriously limited. At this
early stage, there rarely is any substantial callus that can be removed
without ethical concerns. In addition, we used a double and triple
staining technique that allows us to document co-expression of theons.
Cells analyzed Technique Results
Fibroblasts
Osteoblasts
IHC All proteins detected in most
specimens (17/21)
No difference in BMP expression
in delayed healing vs. non-unions
Chondrocytes
Fibroblasts
Osteoblasts
IHC Expression of all BMPs in osteoblasts
Co-localization of BMPs with
receptors in osteoblasts
Variable staining in chondrocytes
and ﬁbroblasts
First to report BMP signaling
in human fractures
Chondrocytes
(hypertrophic and
non-hypertrophic)
Osteoblasts
IHC Expression of all 4 proteins in
endochondral ossiﬁcation and
to lesser extent in osteoblasts
First report of BMP-inhibitors
in human fractures
qPCR, Western
blot, IHC
Up-regulation of BMP4, drm,
gremlin, follistatin and noggin
in non-unions
Up-regulation of BMP7 in healing
tissue
Suggested that up-regulation of
BMP4 and inhibition of BMP7 may
play role in non-unions
Only cartilaginous
tissue examined
IHC Decreased expression of BMP2
and BMP14 in non-unions
No difference in expression of
noggin and chordin
Chondrocytes
Fibroblasts
Osteoblasts
Osteoclasts
IHC In general, stronger expression of
inhibitors than BMPs
Active BMP signaling in osteoblasts
of all sections
Decreased expression of BMP2
and absent expression of BMP7
in cartilage cells of non-unions,
leading to an different balance
between ligand and inhibitor in
non-unions compared to fractures
Table 4
Summary of reports on BMP signaling components in animal fracture healing and non-unions.
Author–year Tissue analyzed BMPs analyzed Cells Technique Results
Ishidou–1995 [26] Rat femoral fracture BMPRIA, BMPRIB Chondrocytes
Fibroblasts
Osteoblasts
IHC Up-regulation of both receptors in all cell types
Onishi–1998 [6] Rat femoral fracture BMP2, BMP4, BMP7
BMPRII
Chondrocytes
Osteoblasts
Osteoclasts
IHC BMP2 and BMP4 expressed in all stages of
both intramembranous and endochondral
ossiﬁcation
BMP7 up-regulated in early phases
BMPRII co-localized with BMP2, BMP4 and BMP7
Yoshimura–2001 [25] Mouse rib fracture noggin, BMP4 Chondrocytes
Osteoblasts
Periosteal and
Endosteal cells
In situ hybridization,
Northern blotting
Co-localization of BMP4 and noggin was the
same in osteoblasts, chondrocytes and
hypertrophic chondrocytes
First to report noggin in animal model
First to suggest that balance between
noggin and BMP4 important for fracture
healing
Niikura–2006 [33] Rat femoral fracture
Normal healing vs.
atrophic non-union
Microarray analysis of
>31,000 genes
Microarray, qRT-PCR Gene expression of BMP2, BMP3, BMP3B,
BMP4, BMP6, BMP7, GDF5, GDF7 and noggin,
drm, sclerostin and BAMBI was signiﬁcantly
lower in non-unions compared to healing
fractures at several time points
Concluded that down-regulation of BMP
components may account for the non-unions
of fractures
Balance between BMPs and their antagonists
is critical for fracture healing
Yu–2010 [37] Mouse tibia fracture
Stabilized
(intramembranous ossiﬁcation)
vs. nonstabilized
(endochondral ossiﬁcation)
BMP2, BMP8, BMPRIA,
BMPRIB, pSmad 1/5/8,
noggin
Chondrocytes
Endothelial cells
Osteoblasts
Osteocytes,
Periosteal cells
IHC In stabilized fractures BMPs and noggin were
detected in isolated inﬂammatory cells and
not detectable in osteoblasts or osteocytes
within new bone. In non- stabilized fractures,
all BMP components are expressed
Concluded that BMP pathway mostly activated
during endochondral ossiﬁcation, and at the
chondro-osseous junction
Dean–2010 [36] Mouse femoral fracture BMP2, BMP4, BMP7,
BMPRIA, BMPRII, noggin,
Dan, chordin, Smad-6,
BAMBI, PRDC, SOST,
Smad-7, GREM1, cerberus
qRT-PCR Noggin up-regulated early, down-regulated
at weeks 2 and 3. Other BMP-inhibitors
divided into 2 groups: (1) PRDC, SOST,
Smad-7, GREM1, cerberus down-regulated
during early fracture healing (2) Dan, chordin,
Smad-6, BAMBI up-regulated 7 days
after fracture
BMPR: BMP receptor; IHC: immunohistochemistry; qRT-PCR: quantitative real-time PCR; GDF: Growth Differentation Factor; PRDC: protein related to Dan/cerberus; GREM1: gremlin;
SOST: sclerostin.
67P. Kloen et al. / Bone 51 (2012) 59–68ligands and its inhibitors in the same cell. Rather than using sequen-
tial slides, we show the co-expression of BMPs, pSmad 1/5/8 and
BMP-inhibitors on the same slide. To the best of our knowledge this
has not been described in human or animal fractures and non-unions.
Conclusion and future directions
Our results add to a growing body of evidence suggesting that
BMP-inhibitors may play a crucial role in bone healing. The potential
of inhibiting the inhibitors is great because of the fact that a single
BMP-inhibitor controls several BMPs, which theoretically would
allow natural synergy to regenerate bone in a more physiological
state. Given this, molecular therapeutics (including gene therapy,
small interfering RNAs, neutralizing antibodies and small molecule
antagonists) might eliminate the need for high doses of BMPs to stim-
ulate fracture healing [47,48]. The data from this study will help our
understanding of the roles of BMPs and their inhibitors in fracture
healing, and further develop new strategies for the treatment of
delayed and non-unions. Future studies should aim at evaluating
the effects of inhibiting BMP-inhibitors on the healing of delayed
and non-unions in various (animal) models.
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